Dr Andrea Chiesi
- Holostem Terapie Avanzate srl
2008- today: CEO and co-founder (www.holostem.com)
Holostem is a spin off of the University of Modena and Reggio Emilia and the Chiesi Group, specialised in the development and manufacturing of advanced therapies, with a particular emphasis on epithelia. Holostem’s manufacturing plant has been GMP certified and a Centralised Procedure for Holoclar® the company’s first product’s (adult autologous corneal epithelium stem cells) has been completed in Europe, making it the first ever stem cell-based product approved in Europe.
- Chiesi Farmaceutici Spa
Member of the Board of Directors (www.chiesigroup.com)
Member of the Executive Committee.
2012- today: Director, R&D Portfolio Management
The role entails the coordination of the planning activities of the projects from the Chiesi R&D, contributing to the definition of the R&D strategic plan and yearly budget, tracking of costs, activities and timelines of projects.
Chiesi’s current projects include:
- Respiratory (NCEs, biologics, new formulations and devices)
- Neonatology (NCEs, biologics, new formulations and devices)
- Special Care:
o Advanced Therapies (gene therapy, mesenchymal stem cells and tissue engineering)
o Enzyme Replacement Therapies
The role also involves the search and management of public grants to R&D projects, the management of the R&D site and the scientific information&intelligence gathering and diffusion.
2009-2012: Director, R&D Project & Portfolio Management
1999-2008: Director, Corporate R&D Planning & Control
2006: ad interim Director of Corporate Drug Development
2002: ad interim Director of the Pharmaceutical Technology Department
1997-1999: Project Leader within the Chiesi R&D
1995-1997: Director, Packaging Engineering Unit
1993-1995: lab analyst in the Packaging Engineering Unit - Pharmaceutical Technology Department